1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends

EpiCast Report: Amyotrophic Lateral Sclerosis - Epidemiology Forecast to 2023

  • May 2014
  • 38 pages
  • GlobalData
Report ID: 2114381

Summary

Table of Contents

EpiCast Report: Amyotrophic Lateral Sclerosis - Epidemiology Forecast to 2023

Summary

Amyotrophic lateral sclerosis (ALS), often referred to as "Lou Gehrig's Disease," is a rare, but fatal, progressive neurodegenerative disease that affects the nerve cells in the brain and the spinal cord. ALS severely impacts physical functioning and initially presents with muscle twitching, weakness in an arm or leg, or with slurring of speech. Eventually, people with ALS lose their ability to control the muscles needed to move, speak, eat, and breathe, which ultimately leads to death. The progressively degenerative course of the condition is a great burden for both patients and caregivers, as well as for society.

GlobalData epidemiologists forecast that the diagnosed prevalent cases of ALS in the 7MM will grow by 13.5% over the next decade, from 32,698 diagnosed prevalent cases in 2013 to 37,122 diagnosed prevalent cases in 2023. Throughout the forecast period, the US will have the highest numbers of diagnosed prevalent cases of ALS, followed by Japan.

To develop the epidemiological forecast for the diagnosed prevalent cases of ALS in the 7MM, GlobalData epidemiologists obtained the diagnosed prevalence data for ALS from peer-reviewed journals and population-based studies in the respective markets and used a consistent methodology to ensure comparability of the results. A major strength of GlobalData’s epidemiological analysis is the use of country-specific studies that provided the diagnosed prevalence of ALS using uniform diagnostic criteria based on the El Escorial criteria or the International Classification of Diseases, Ninth Revision (ICD-9), criteria (ICD-9 code for ALS = 335.2), to allow for a meaningful comparison of the diagnosed prevalent cases of ALS in these markets. Furthermore, the diagnosed prevalent cases of ALS in each of the 7MM were further segmented by age and sex in order to provide a more detailed analysis of the patient population.

Scope

- The Amyotrophic lateral sclerosis (ALS) EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends for ALS in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed prevalent cases of ALS segmented by age (=40 years) and sex in these markets.
- The ALS epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

- Develop business strategies by understanding the trends shaping and driving the global ALS market.
- Quantify patient populations in the global ALS market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for ALS therapeutics in each of the markets covered.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Ahmad helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Frontier Pharma: Alzheimer’s Disease and Associated Indications - Exceptional Level of First-in-Class Innovation within AD, and Diverse Range of Therapies in Development for Disorders Such as Anxiety and Depression

  • $ 6995
  • Industry report
  • May 2017
  • by GBI Research

Frontier Pharma: Alzheimer’s Disease and Associated Indications - Exceptional Level of First-in-Class Innovation within AD, and Diverse Range of Therapies in Development for Disorders Such as Anxiety ...

Therapeutic Breakthroughs in Alzheimer’s and Parkinson’s Diseases

  • $ 4950
  • Industry report
  • April 2017
  • by Frost & Sullivan

Disease-Modifying Treatments Likely to Transform the Clinical Management of Alzheimer’s and Parkinson’s Diseases The research service primarily encompasses comprehensive analyses of key emerging therapies ...

Amyotrophic lateral sclerosis (ALS)- Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • March 2017
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Amyotrophic lateral sclerosis (ALS) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of ...


Download Unlimited Documents from Trusted Public Sources

Dementia Statistics in the UK

  • June 2017
    9 pages
  • Dementia  

  • United Kingdom  

View report >

Mental Health Statistics in the UK - Forecast

  • June 2017
    6 pages
  • Mental Health  

    Mental Health  

    Dementia  

  • United Kingdom  

View report >

Mental Health Statistics in the UK

  • June 2017
    41 pages
  • Mental Health  

    Anxiety Disorde...  

    Defence  

  • United Kingdom  

    Europe  

    Afghanistan  

View report >

Dementia Statistics

22 days ago

Related Market Segments :

Dementia

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.